Addendum
Ticagrelor (prevention of atherothrombotic events after myocardial infarction) – Addendum to Commission A16-15
Report documents
-
Addendum
Ticagrelor (prevention of atherothrombotic events after myocardial infarction) – Addendum to Commission A16-15
Press releases
Ticagrelor for prevention after myocardial infarction: added benefit called into question by data subsequently submitted
Greater consistency and certainty of conclusions of the results regarding harmful aspects
Additional information
Federal Joint Committee (G-BA)
2016-09-15 A G-BA decision was published.
Project details
- Project no.
- A16-52
- Commission
- Commission awarded on 10.08.2016 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Heart and circulation
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Ticagrelor (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed